Evidence map›Paper›PMID 40583276›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025

Targeting NLRP3/caspase-1/GSDMD to treat inner ear injury from labyrinthine hemorrhage.

Qiong Wu, Mingwei Xu, Yuan Yao, Tianyu Gong, Qin Zhang, Yulian Jin, Jun Yang, Qing Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Targeting NLRP3/caspase-1/GSDMD to treat inner ear injury from labyrinthine hemorrhage.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qiong WuDepartment of Otolaryngology, Head and Neck Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China; Ear Institute, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China; Shanghai Key Laboratory of Translational Medicine in Ear and Nose Diseases, Shanghai 200092, China.
Mingwei XuDepartment of Otolaryngology, Head and Neck Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China; Ear Institute, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China; Shanghai Key Laboratory of Translational Medicine in Ear and Nose Diseases, Shanghai 200092, China.
Yuan YaoDepartment of Otolaryngology, Head and Neck Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China; Ear Institute, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China; Shanghai Key Laboratory of Translational Medicine in Ear and Nose Diseases, Shanghai 200092, China.
Tianyu GongDepartment of Otolaryngology, Head and Neck Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China; Ear Institute, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China; Shanghai Key Laboratory of Translational Medicine in Ear and Nose Diseases, Shanghai 200092, China.
Qin ZhangDepartment of Otolaryngology, Head and Neck Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China; Ear Institute, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China; Shanghai Key Laboratory of Translational Medicine in Ear and Nose Diseases, Shanghai 200092, China.
Yulian JinEar Institute, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China; Shanghai Key Laboratory of Translational Medicine in Ear and Nose Diseases, Shanghai 200092, China; Diagnosis and Treatment Center of Hearing Impairment and Vertigo, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China. Electronic address: jinyulian8548@xinhuamed.com.cn.
Jun YangDepartment of Otolaryngology, Head and Neck Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China; Ear Institute, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China; Shanghai Key Laboratory of Translational Medicine in Ear and Nose Diseases, Shanghai 200092, China. Electronic address: yangjun@xinhuamed.com.cn.
Qing ZhangDepartment of Otolaryngology, Head and Neck Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China; Ear Institute, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China; Shanghai Key Laboratory of Translational Medicine in Ear and Nose Diseases, Shanghai 200092, China. Electronic address: zhangqing03@xinhuamed.com.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sudden sensorineural hearing loss (SSNHL) is a prevalent condition in otolaryngology with poorly understood mechanisms. Inner ear labyrinthine hemorrhage (IELH) is a potentially significant cause. Our study focused on the NLR family pyrin domain containing 3 (NLRP3) inflammasome activation following IELH and the protective role of the NLRP3 inhibitor CY-09. In mice with IELH, significant increases in hearing thresholds and vestibular dysfunction were observed compared with control groups. The activation of the NLRP3 inflammasome and other pro-inflammatory factors were markedly elevated, leading to potential damage in cochlear and vestibular hair cells via the Gasdermin D (GSDMD)-mediated pyroptosis pathway. Treatment with CY-09 significantly ameliorated hearing loss and vestibular dysfunction via inhibition of the NLRP3 inflammasome and associated cell pyroptosis. These results highlight the critical roles of the NLRP3 inflammasome and pyroptosis in IELH-induced SSNHL and suggest the NLRP3/caspase-1/GSDMD pathway as a therapeutic target for managing this condition. This study offers a new theoretical basis for the potential clinical management of SSNHL.

Indexed as

Caspase 1Ear, InnerHemorrhageIntracellular Signaling Peptides and ProteinsLabyrinth DiseasesNLR Family, Pyrin Domain-Containing 3 ProteinPhosphate-Binding ProteinsAnimalsDisease Models, AnimalGasderminsHearing Loss, SensorineuralHumansInflammasomesMicePyroptosisCasp1 protein, mouseCaspase 1GasderminsGsdmd protein, mouseInflammasomesIntracellular Signaling Peptides and ProteinsNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mousePhosphate-Binding Proteinsacute inner ear injuryCY-09 inhibitorinflammasome inhibitorinner ear hemorrhapglabyrinthine hemorrhageNLRP3 inflammasomepyroptosissudden sensorineural hearing losstreatment

Identifiers

PMID40583276
PMCPMC12848244

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.